Zilretta (triamcinolone acetonide ER) / Pacira 
Welcome,         Profile    Billing    Logout  
 2 Diseases   7 Trials   7 Trials   248 News 


123»
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment closed:  Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) -  Dec 27, 2024   
    P3,  N=65, Active, not recruiting, 
    In addition, outcomes in the novel cryoneurolysis and conventional IA-CS were similar to one another and better than those in IA-HA and IA-NSAIDs. Recruiting --> Active, not recruiting
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial primary completion date:  CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) -  Apr 5, 2024   
    P4,  N=150, Enrolling by invitation, 
    Use of TA-ER was associated with a clinically meaningful reduction in hyperglycemia versus TA-IR. Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira, Bydureon (exenatide XR once-weekly) / AstraZeneca
    Mapping the drug-loading design space of long-acting cross-linked microparticles (In-person; Galerie 6 (New Orleans Marriott)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11653;    
    Trial primary completion date: Mar 2024 --> Mar 2025 Polymeric microparticles (MPs) are clinically well-established formulations (e.g., Lupron Depot
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira, Exparel (bupivacaine liposome injectable suspension) / Pacira
    LL16: Lunch and Learn: Differentiating Your Orthopaedic Practice: Hear from the Leaders in Pain Management Innovation (Hall A, Booth 162, Ask an Expert Theater) -  Jan 19, 2024 - Abstract #AAOS2024AAOS_4288;    
    Differentiating your orthopaedic practice: a panel discussion from leaders in pain management innovation. Hear from each panelist and how they use EXPAREL, iovera, and/or ZILRETTA to provide individual and innovative solutions to meet the unique needs of their patients via a multimodal, non-opioid approach.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial primary completion date:  Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) -  Jan 4, 2024   
    P3,  N=65, Recruiting, 
    Hear from each panelist and how they use EXPAREL, iovera, and/or ZILRETTA to provide individual and innovative solutions to meet the unique needs of their patients via a multimodal, non-opioid approach. Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date, Trial primary completion date:  Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) -  Oct 12, 2023   
    P3,  N=65, Recruiting, 
    Cryo was associated with somewhat more improvement than IA-NSAID and IA-CS in pain and function, respectively. Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira, Monovisc (sodium hyaluronate) / Anika Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Trial Comparing Three Single Dose Injections for Knee Osteoarthritis (clinicaltrials.gov) -  Apr 10, 2023   
    P4,  N=6, Terminated, 
    Potential participants are unwilling to participate in the study due to the randomziation and blinding. Both aspects are needed to ensure a robust comparison between groups.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment closed, Trial completion date, Trial primary completion date:  Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis (clinicaltrials.gov) -  Oct 6, 2022   
    P2,  N=22, Active, not recruiting, 
    These data indicate improvement in chair stand performance through 12 weeks post-injection and sustained improvement in participant-reported physical function through 24-week follow-up in adults with bilateral painful knee OA treated with TA-ER. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  SLAM: Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=6, Terminated, 
    Trial primary completion date: Aug 2022 --> Aug 2023 N=30 --> 6 | Trial completion date: Oct 2023 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Jul 2022; Funding Termination
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion, Trial completion date, Trial primary completion date:  Effect of Zilretta Injection (clinicaltrials.gov) -  May 20, 2022   
    P1,  N=35, Completed, 
    N=30 --> 6 | Trial completion date: Oct 2023 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Jul 2022; Funding Termination Recruiting --> Completed | Trial completion date: Sep 2023 --> Jan 2022 | Trial primary completion date: Sep 2023 --> Jan 2022
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Journal:  Nonsurgical Management of Osteoarthritis of the Knee: What You Should Be Injecting Now and in the Future. (Pubmed Central) -  Mar 15, 2022   
    The recent (FDA approval in 2017) introduction of a sustained-release corticosteroid (triamcinolone acetonide extended-release) offers significantly longer benefit than standard cortisone products and with substantially lower concentration levels of chondrocyte exposure to the steroid...Finally, the past 15 years have seen an explosion in the use of biologics including platelet-rich plasma and pluripotential (often termed stem) cells. The science behind their use and efficacy is evolving and continued study is warranted.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date, Trial primary completion date:  Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) -  Nov 26, 2021   
    P3,  N=65, Recruiting, 
    Systemic TA exposure was markedly lower in TA-ER-treated patients, consistent with the PK profile observed in knee osteoarthritis. Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Sep 2021 --> Sep 2023
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date, Trial primary completion date:  Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis (clinicaltrials.gov) -  Oct 26, 2021   
    P2,  N=24, Recruiting, 
    Lower peak and systemic TA exposure following TA-ER suggests TA-ER could potentially confer an improved systemic safety profile over TAcs. Trial completion date: May 2021 --> Sep 2022 | Trial primary completion date: Feb 2021 --> Sep 2022
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Flexion Therap
    Preclinical, Journal:  Dynamic weight-bearing test during jumping: A sensitive outcome measure of chronic osteoarthritis pain in rats. (Pubmed Central) -  Sep 16, 2021   
    An intra-articular injection of Zilretta (triamcinolone acetonide extended-release injectable suspension) attenuated OA-induced jump incapacitance after 8 days compared with DMM rats receiving vehicle (p = 0.069)...In conclusion, the dynamic weight-bearing test during jumping represents a novel method to characterize joint pain symptoms even in a slowly progressive OA rat model. It is sensitive, observer independent, relates to clinically relevant endpoints and demonstrates backtranslation of a drug that is approved for the treatment of OA knee pain.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment status:  CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) -  Jun 23, 2021   
    P4,  N=150, Enrolling by invitation, 
    It is sensitive, observer independent, relates to clinically relevant endpoints and demonstrates backtranslation of a drug that is approved for the treatment of OA knee pain. Recruiting --> Enrolling by invitation
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Flexion Therap
    [VIRTUAL] Interim results: the effect of intra-articular extended-release triamcinolone acetonide on OARSI-recommended physical performance measures in adults with bilateral symptomatic knee OA () -  May 3, 2021 - Abstract #OARSI2021OARSI_360;    
    While the efficacy of TA-ER on reducing pain due to knee OA has beenreported, the effects on physical performance have not been fully investigated.Given the incomplete association between reduction in pain and reduction in functionallimitations, the primary aim of this study was to demonstrate theeffects of intra-articular injection of TA-ER on OARSI-recommended physicalperformance measures (30-second chair stand test, stair ascent time, and 40mfast-paced walking time) in adults with bilateral symptomatic knee OA. Secondarily,this study evaluated patient-reported physical function (KOOS-PS), quality oflife (KOOS-QoL) and knee pain (NRS) 6, 12 and 24 weeks following injection of bilateral knees with TA-ER.
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date:  The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA (clinicaltrials.gov) -  Apr 27, 2021   
    P4,  N=73, Active, not recruiting, 
    Secondarily,this study evaluated patient-reported physical function (KOOS-PS), quality oflife (KOOS-QoL) and knee pain (NRS) 6, 12 and 24 weeks following injection of bilateral knees with TA-ER. Trial completion date: Mar 2021 --> Aug 2021
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    New P1 trial:  ZILRETTA (clinicaltrials.gov) -  Apr 4, 2021   
    P1,  N=50, Recruiting, 
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment open:  CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) -  Mar 12, 2021   
    P4,  N=150, Recruiting, 
    Trial completion date: Mar 2021 --> Aug 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Trial completion date:  CoMeT: Corticosteroid Meniscectomy Randomized Trial (clinicaltrials.gov) -  Feb 8, 2021   
    P4,  N=150, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Apr 2025
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment open, Trial completion date, Trial primary completion date:  Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis (clinicaltrials.gov) -  Nov 30, 2020   
    P2,  N=24, Recruiting, 
    It was demonstrated here for the first time that elevated temperature-accelerated testing does not work for all PLGA-based microsphere products. Not yet recruiting --> Recruiting | Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jul 2020 --> Feb 2021